The suffix “-mab” is shorthand for “monoclonal antibody,” and it appears at the end of drug names because the World Health Organization’s naming program assigns shared stems to drugs that belong to the same pharmacological family. Since monoclonal antibodies emerged as a therapeutic class in the 1980s, every substance built around an antibody’s variable domain received a name ending in -mab. By 2022, that stem had been used in 879 approved nonproprietary names, making it one of the most recognizable patterns in all of medicine.1PubMed Central. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system But that ubiquity has also created a problem, and the naming rules are now changing in ways that will reshape the pharmacy shelf over the next decade.
What the Name Actually Tells You
Drug names like trastuzumab, adalimumab, and pembrolizumab look like alphabet soup, but they are engineered to carry useful information. The WHO’s International Nonproprietary Names (INN) system is the reason. Every active pharmaceutical ingredient gets a generic name (separate from its brand name), and that generic name is supposed to signal what kind of drug it is. For monoclonal antibodies, the common stem -mab sits at the end, telling anyone who reads a prescription that this is an antibody-based therapy.
Before 2017, the names packed in even more detail. A series of letter clusters (called substems or infixes) indicated the antibody’s intended target and its species of origin. A drug name ending in -ximab meant a chimeric antibody (part mouse, part human). One ending in -zumab was humanized, and -umab meant fully human. A middle chunk like -tu- pointed to a tumor target, -li- to the immune system, and -ci- to the cardiovascular system. So rituximab could be decoded: ri- (a unique prefix), -tu- (tumor target), -xi- (chimeric), -mab (monoclonal antibody). The system was a kind of built-in cheat sheet for clinicians.
Not every name followed the rules perfectly, though. A study analyzing whether approved drugs actually contain the correct stem found that up to about 40% of the broader INN catalog may not use the preferred stem in accordance with its definition, suggesting the system’s clarity has limits in practice.2PLoS ONE. Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names For monoclonal antibodies specifically, the naming was more consistent because the -mab stem was applied systematically. But as the class expanded, the infixes were quietly dropped, starting with the species substem in 2017. By that point, almost all new antibodies reaching the market were fully human, making the -u- infix redundant.
Why There Are So Many of Them
The sheer number of -mab drugs reflects how versatile antibodies turned out to be as medicines. The basic idea is straightforward: an antibody is a protein that the immune system naturally produces to lock onto a specific molecular target. Scientists figured out how to produce a single type of antibody in bulk (hence “monoclonal,” meaning from one clone of cells), then point it at a disease-related target. The first therapeutic monoclonal antibody reached the U.S. market in 1986, and by November 2014, forty-seven monoclonal antibody products had been approved in the U.S. or Europe.3PubMed Central. The therapeutic monoclonal antibody market That number has continued to climb, with new approvals arriving at a steady pace.
Part of the explosion comes from the range of targets these drugs can hit. Therapeutic monoclonal antibodies and related fusion proteins bind at least 185 different molecular targets across cancer, autoimmune disease, cardiovascular conditions, and more.4ScienceDirect. Therapeutic Antibody Engineering – Chapter 8 – Monoclonal antibody targets and mechanisms of action Some targets attract heavy competition: the top 16 targets alone account for 133 of the known antibody drugs, while the remaining 263 spread across 169 different targets. That kind of breadth is unusual in drug development, where most drug classes share a much narrower range of mechanisms.
How the Antibodies Became More Human
The earliest therapeutic monoclonal antibodies were made entirely from mouse immune cells. They worked as hoped in the lab, binding their targets with impressive precision. But the human body recognized them as foreign proteins and mounted an immune response against them, which limited how long the drugs stayed effective and sometimes caused serious allergic reactions.
The solution came in stages. First, researchers created chimeric antibodies by splicing the mouse antibody’s target-binding region onto a human antibody’s structural backbone. These chimeric versions circulated in the body roughly six times longer than fully mouse antibodies and triggered far fewer immune reactions.5PubMed Central. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response Next came humanized antibodies, which kept only the smallest critical binding loops from the mouse and replaced everything else with human sequence. Finally, technologies like phage display libraries and transgenic mice enabled the creation of fully human antibodies, with no mouse components at all. Drugs like adalimumab and panitumumab were generated using these platforms.6PubMed. Fully human antibodies from transgenic mouse and phage display platforms
Each step reduced the chance that a patient’s immune system would reject the drug. Human and chimeric antibodies are much less likely to provoke anti-antibody responses than intact mouse antibodies after a single injection, though repeated dosing can still occasionally trigger immune reactions even with fully human designs.7PubMed Central. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? This engineering progression is why the names evolved too: the naming system’s species infixes tracked whether a drug was mouse-derived (-o-), chimeric (-xi-), humanized (-zu-), or fully human (-u-). As fully human antibodies became the default, that part of the name lost its informational value.
What Monoclonal Antibodies Do Once They Reach Their Target
Locking onto a target is just the first step. What happens next depends on the drug’s design and the disease it is treating. The known mechanisms of action for therapeutic antibodies are surprisingly varied:
- Blocking a signal: The antibody can grab onto a protein that a cancer cell or inflammatory cell needs to communicate, essentially cutting the phone line. This is how many anti-inflammatory antibodies work when they neutralize signaling molecules like TNF-alpha or interleukin-6.
- Flagging cells for destruction: Once an antibody binds to the surface of a target cell, it can recruit the patient’s own immune cells to finish the job. Natural killer cells perform antibody-dependent cellular cytotoxicity (ADCC), and macrophages perform antibody-dependent cellular phagocytosis (ADCP), both triggered by the antibody acting as a beacon.8PubMed Central. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
- Activating complement: Some antibodies trigger the complement system, a cascade of blood proteins that can punch holes in cell membranes. This complement-dependent cytotoxicity varies widely depending on the specific antibody, the target protein, and the tumor type.
- Triggering cell death directly: Certain antibodies can induce apoptosis (programmed cell death) in the target cell without needing immune-cell backup.
Researchers have also engineered antibodies whose structural backbones are tweaked to amplify specific effects. By modifying the Fc region (the “tail” of the antibody that interacts with immune cells), scientists can boost ADCC or complement activation beyond what a natural antibody would achieve.9Methods. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions This kind of engineering is part of why the drug class has kept expanding: you can take the same basic antibody architecture and tune it for different therapeutic goals.
Antibody-Drug Conjugates and Other Hybrid Designs
The -mab suffix also covers drugs that go well beyond a naked antibody floating through the bloodstream. One of the fastest-growing subcategories is the antibody-drug conjugate (ADC), which links a monoclonal antibody to a toxic payload through a stable chemical linker. The antibody acts as a homing device, carrying the toxic molecule directly to the tumor cell and releasing it there. Most ADCs developed so far target cancer, but the concept has potential for other diseases.10PubMed Central. Introduction to Antibody-Drug Conjugates The appeal is obvious: you get the precision of the antibody combined with the killing power of a chemotherapy drug, ideally sparing healthy tissue from most of the damage.11PubMed. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads
Bispecific antibodies are another innovation that falls under the -mab umbrella. Instead of binding one target, these engineered molecules grab two different targets simultaneously. One common design uses one arm to latch onto a tumor cell and the other arm to grab a T cell (a potent immune cell), physically dragging the two together and forcing an immune attack on the cancer.12PubMed Central. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies These T-cell engagers typically connect two small antibody fragments via a flexible linker, with one fragment targeting a T-cell protein (usually CD3) and the other targeting a tumor-specific protein like CD19 or BCMA.13Journal of Pharmacology and Experimental Therapeutics. Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies The approach can disrupt multiple signaling pathways at once, offering treatment strategies that conventional single-target antibodies cannot.14PubMed Central. Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies
Then there are nanobodies, derived from the unusual heavy-chain-only antibodies found naturally in camels, llamas, and alpacas. The binding fragment of these antibodies is roughly one-tenth the size of a conventional antibody, yet retains comparable specificity and binding strength.15PubMed Central. Nanoantibodies: small molecules, big possibilities Their tiny size, high stability, and water solubility make them easy to manufacture and potentially useful in situations where a full-sized antibody cannot reach.16PubMed Central. A comprehensive comparison between camelid nanobodies and single chain variable fragments The first nanobody-based drug, caplacizumab, was approved in 2018 for a rare blood-clotting disorder.
Why -Mab Is Being Retired
With 879 names already built on the -mab stem, the WHO’s naming experts ran into a practical wall: they were running out of distinguishable names. When hundreds of drugs share the same four-letter ending and many also share target-related infixes, the risk of confusion between names climbs. A prescriber writing quickly or a pharmacist reading a smudged label has fewer letters of difference to work with. In October 2021, the WHO made what it described as a “radical decision” and voted to stop using -mab for new antibody-based drugs entirely.1PubMed Central. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system
In its place, four new stems were introduced: -tug, -bart, -mig, and -ment. Each is assigned based on the structural type of the antibody product. A conventional naked monoclonal antibody gets one stem, an antibody-drug conjugate gets another, and so on. The idea is to distribute new names across multiple endings so no single suffix gets as crowded as -mab did. Existing drugs keep their names (you will still see trastuzumab and pembrolizumab), but newly approved antibodies will increasingly arrive with unfamiliar endings. The transition will take years, since drugs that were already deep in development when the rules changed may still receive -mab names.
For clinicians and patients, the shift means adjusting long-held mental shortcuts. For three decades, seeing -mab at the end of a drug name instantly signaled “this is an antibody therapy.” That shortcut will erode over time as the new stems become common. Whether the replacement system will be as intuitive is an open question. Four stems carrying structural information is arguably more useful than one stem carrying none, but it also demands that prescribers learn a new code.
How Monoclonal Antibodies Are Manufactured
One reason these drugs cost so much more than a typical small-molecule pill is the complexity of making them. Monoclonal antibodies are large, intricate proteins that must be produced by living cells rather than synthesized in a chemical reactor. The workhorse of the industry is the Chinese hamster ovary (CHO) cell line, which has been used for recombinant protein production for decades and remains the most common platform for antibody manufacturing.17PubMed Central. Advances in recombinant antibody manufacturing CHO cells are grown in large bioreactors under carefully controlled conditions, and the antibody they secrete is then harvested and purified through multiple steps.
Production yields have improved dramatically over the years. Advances in cell-line engineering, growth media, and bioreactor design have pushed output from milligrams per liter in the early days to multi-gram-per-liter titers now. Even so, the manufacturing process remains expensive and time-consuming compared to pressing a tablet. Each batch has to be tested for purity, potency, and the absence of contaminants, and even small changes in production conditions can alter the drug’s properties. This sensitivity is part of why “biosimilars” (the antibody equivalent of generic drugs) face a more demanding approval path than generic small-molecule medicines.
Biosimilars and the Extra Suffix on the Label
As blockbuster antibody drugs have lost patent protection, biosimilar versions have entered the market. These are not identical copies of the original, because no living-cell production process can produce an exact replica of a complex protein. Instead, they are shown to be highly similar with no clinically meaningful differences. To distinguish them in prescribing records and safety tracking, the U.S. FDA requires that all biological products approved after March 2020 carry a four-letter suffix appended to their nonproprietary name.18PubMed Central. Naming Convention, Interchangeability, and Patient Interest in Biosimilars So while the original drug might be adalimumab, a biosimilar version could be adalimumab-adaz or adalimumab-bwwd.
The suffix convention was designed to make it easier to trace adverse events back to the specific product a patient received. In practice, though, the extent to which these suffixes actually get incorporated into reporting remains unclear.19PubMed Central. Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting If a nurse documents a reaction under just “adalimumab” without the suffix, the system loses the ability to distinguish which manufacturer’s product was involved. The suffixes are meaningless strings by design (they are not supposed to suggest anything about the product), which makes them harder for busy clinicians to remember and record correctly.
Getting an Antibody Into a Patient
Most monoclonal antibodies are given as intravenous infusions, which means a patient sits in a clinic for anywhere from 30 minutes to several hours while the drug drips into a vein. This is partly because antibodies are large molecules that cannot survive the digestive tract if swallowed as a pill, and partly because the doses involved are substantial, sometimes hundreds of milligrams at a time.
Subcutaneous injection (a shot under the skin, like an insulin pen) has become an alternative for some antibodies, which is far more convenient for patients. The challenge is volume: the subcutaneous space does not easily accept the large fluid volumes that intravenous infusions deliver. Researchers solved this for drugs like rituximab and trastuzumab by concentrating the antibody formulation roughly 12-fold and adding an enzyme called recombinant human hyaluronidase, which temporarily opens up the tissue under the skin to accommodate more than the usual two to three milliliters of fluid.20British Journal of Cancer. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase The result is a treatment session measured in minutes rather than hours, often administered at home rather than in a clinic. This shift has meaningfully changed quality of life for patients on long-term antibody therapy, particularly in oncology and autoimmune disease, where treatment may continue for years.
Oral antibody delivery remains largely out of reach for systemic treatment. The stomach’s acidic environment and the enzymes of the small intestine shred protein molecules. Research into oral formulations exists, but no oral monoclonal antibody has made it to market for systemic use. Some antibodies designed to act locally within the gut are an exception, but for anything that needs to reach the bloodstream, needles remain the standard.